FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.
— Read on www.specialtypharmacytimes.com/

6 thoughts on “FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma”

Comments are closed.